immun
spectrum
sever
acut
respiratori
syndrom
sar
poorli
understood
defin
dynam
immun
spectrum
sar
serum
level
cytokin
chemokin
immunoglobulin
complement
specif
antibodi
sarsassoci
coronaviru
sarscov
assay
enzymelink
immunosorb
assay
elisa
phenotyp
peripher
lymphocyt
analyz
flow
cytometri
sarsinfect
patient
result
show
interleukin
il
transform
growth
factor
b
tgfb
continu
upregul
entireti
sar
regul
activ
normal
cellexpress
secret
rant
level
decreas
monocyt
chemoattract
elev
acut
patient
immunoglobulin
complement
elev
first
month
sar
serumposit
rate
titer
specif
igm
igg
antibodi
respond
sarscov
peak
day
onset
sar
lymphocyt
decreas
significantli
acutephas
lymphocyt
decreas
convalesc
patient
conclus
sarscov
seem
elicit
effect
humor
immun
inhibit
cellular
immun
especi
memori
lymphocyt
time
prolong
overproduct
tgfb
may
play
import
role
diseas
sever
acut
respiratori
syndrom
sar
caus
sarsassoci
coronaviru
sarscov
known
human
coronavirus
usual
infect
upper
respiratori
tract
caus
common
cold
wherea
sarscov
infect
lower
respiratori
tract
lead
pulmonari
destruct
although
antibodi
induct
lymphopen
respons
sarscov
briefli
describ
elsewher
precis
immun
inflammatori
respons
follow
sarscov
infect
remain
unclear
moreov
rapidli
report
result
author
deal
mere
one
two
aspect
antivir
immun
ie
either
antibodi
induct
chang
lymphocyt
alter
cytokin
initi
studi
show
lung
also
immun
cell
target
sarscov
overal
immun
spectrum
sar
profil
humor
cellular
immun
import
sar
whether
cytokin
chemokin
play
role
pathogenesi
sar
statu
immun
memori
function
lymphocyt
sar
particularli
import
explor
full
inform
descript
immun
respons
pathogenesi
sar
greatli
help
us
understand
pathogen
mechan
well
improv
patient
manag
develop
vaccin
complet
control
sar
epidem
panel
cytokin
cytokin
interferon
c
ifnc
tumor
necrosi
factor
tnf
interleukin
il
cytokin
reflect
overal
balanc
within
immun
system
chemokin
function
briefli
inflammatori
process
act
regulatori
bridg
molecul
innat
acquir
immun
complement
system
import
compon
innat
immun
major
antivir
effector
besid
solubl
mediat
mention
lymphocyt
especi
b
lymphocyt
play
central
role
specif
antivir
immun
clear
viru
thu
decid
defin
immun
respons
profil
focus
mainli
cytokin
chemokin
balanc
lymphocyt
subtyp
give
overview
immun
spectrum
sarscov
therefor
character
system
spectrum
immun
inflammatori
respons
sarsinfect
healthcar
worker
result
indic
sarscov
seem
elicit
effect
humor
immun
inhibit
cellular
immun
imbal
immun
ie
prolong
overproduct
transform
growth
factor
b
tgfb
may
play
import
role
diseas
observ
hypothes
creat
imbal
immun
function
could
associ
sar
pathogenesi
direct
destruct
lymphocyt
sar
indirectli
impair
cellular
immun
sarsinduc
humor
mediat
februari
march
identifi
hospitalcontactexpos
healthcar
worker
nurs
physician
radiologist
cleric
staff
traine
paramed
particip
care
sar
patient
region
whose
diseas
met
case
definit
sar
revis
chines
ministri
health
april
second
affili
hospit
sun
yatsen
univers
guangzhou
patient
enrol
studi
definit
closecontact
histori
person
suspect
alanin
aminotransferas
alt
aspart
aminotransferas
ast
serum
creatinin
level
elev
significantli
within
day
onset
sar
describ
previous
approxim
patient
suffer
hypoxemia
day
latenc
period
prior
onset
symptom
patient
develop
fever
temperatur
h
rigor
tabl
patient
present
dyspnea
pleurisi
myalgia
patient
report
product
cough
malais
mild
leukopenia
thrombocytopenia
observ
initi
present
patient
within
week
onset
sar
signific
leukopenia
decreas
per
l
thrombocytopenia
decreas
per
l
observ
alt
present
case
similar
previou
report
three
patient
treat
mechan
ventil
empir
treatment
antivir
regimen
gamma
globulin
andor
corticosteroid
patient
surviv
recov
symptom
plusminu
valu
mean
sd
normal
rang
follow
red
blood
cell
count
per
l
hemoglobin
gdl
white
blood
cell
count
per
l
lymphocyt
percentag
platelet
per
l
alt
ul
ast
ul
creatinin
patient
good
prognos
sequela
observ
date
control
subject
healthi
adult
volunt
male
femal
mean
age
year
old
sampl
time
sequenc
similar
studi
subject
inform
consent
obtain
patient
institut
review
board
research
ethic
board
particip
institut
approv
studi
blood
sampl
patient
consecut
collect
day
admiss
hospit
convalesc
phase
diseas
acutephas
defin
period
onset
diseas
time
patient
becam
clinic
stabl
convalesc
phase
defin
period
releas
hospit
soon
peripher
blood
mononuclear
cell
pbmc
convalesc
patient
isol
use
hypaqueficol
promega
frozen
liquid
nitrogen
vv
plu
vv
autolog
serum
serum
concentr
cytokin
includ
interleukin
ifnc
tnfb
tgfb
chemokin
includ
regul
activ
normal
cellexpress
secret
rant
monocyt
chemoattract
measur
use
quantit
sandwich
enzym
immunoassay
techniqu
elisa
kit
r
system
minneapoli
mn
polystyren
micropl
precoat
recombin
human
tgfb
solubl
receptor
type
ii
murin
monoclon
antibodi
ifnc
tnfb
rant
briefli
assay
diluent
ad
well
specifi
serum
sampl
standard
control
buffer
ad
h
incub
room
temperatur
plate
aspir
wash
three
four
time
two
hundr
micolit
conjug
ad
incubationwash
repeat
substrat
solut
ad
plate
incub
room
temperatur
min
final
stop
solut
ad
optic
densiti
od
read
within
min
micropl
reader
clinibio
austria
nm
refer
wavelength
set
nm
gener
humor
immun
paramet
iga
igg
igm
evalu
serum
sampl
use
beckman
array
system
beckman
coulter
galway
ireland
specif
igm
igg
antibodi
respond
sarscov
measur
enzymelink
immunosorb
assay
elisa
use
sar
antibodi
assay
kit
develop
chines
academi
militari
scienc
chines
academi
medicin
huada
co
ltd
beij
polystyren
micropl
precoat
lysat
sarscov
sarscovinfect
cell
briefli
assay
diluent
ad
well
serum
sampl
standard
control
buffer
ad
incub
min
plate
aspir
wash
five
time
one
hundr
microlit
conjug
murin
antihuman
igg
ad
plate
incub
min
wash
five
time
substrat
solut
substrat
solut
b
sequenti
ad
plate
incub
room
temperatur
min
final
stop
solut
ad
od
read
within
min
micropl
reader
clinibio
austria
nm
refer
wavelength
set
nm
acutephas
flow
assay
perform
realtim
sampl
heparin
peripher
blood
collect
acutephas
patient
underw
red
blood
cell
lysi
use
trishclnh
cl
ph
wash
pb
label
fitc
apcandor
peconjug
antibodi
bd
pharmingen
convalescentphas
flow
assay
perform
frozen
sampl
recov
pbmc
patient
control
subject
cultur
overnight
gibco
brl
supplement
human
ab
type
serum
uml
gentamicin
gibco
brl
label
fitc
apcandor
peconjug
murin
antihuman
monoclon
antibodi
phenotyp
lymphocyt
sequenti
analyz
flow
cytometri
facscalibur
color
system
bd
bioscienc
ca
us
data
given
mean
standard
deviat
sd
unless
otherwis
specifi
result
compar
use
student
ttest
spearman
correl
test
analysi
varianc
anova
use
softwar
p
bilater
consid
statist
signific
overal
tgfbwere
continu
overproduc
entir
cours
sar
infect
indic
cytokin
respons
compar
normal
control
level
sar
patient
chang
significantli
within
first
month
decreas
month
fig
p
correl
coeffici
oneway
anova
minimum
detect
dose
pgml
notabl
month
level
decreas
lowest
point
pgml
less
normal
control
level
p
oneway
anova
ifnc
alter
either
acut
convalesc
phase
compar
normal
control
group
fig
minimum
detect
dose
pgml
tnfb
significantli
decreas
within
first
week
month
fig
p
respect
oneway
anova
minimum
detect
dose
pgml
gradual
return
normal
level
next
month
level
serum
sar
patient
continu
elev
month
observ
studi
time
normal
control
level
fig
p
correl
coeffici
oneway
anova
minimum
detect
dose
pgml
serum
level
und
tectabl
patient
healthi
volunt
fig
minimum
detect
dose
pgml
tgfb
increas
sar
patient
throughout
test
period
particularli
month
fig
p
correl
coeffici
oneway
anova
minimum
detect
dose
pgml
observ
chang
cytokin
level
correl
administr
glucocorticoid
p
spearmen
correl
analysi
two
b
chemotact
peptid
assay
elisa
patient
concurr
control
show
level
rant
decreas
acut
convalescentphas
patient
fig
minimum
detect
dose
pgml
wherea
elev
around
acut
patient
return
normal
level
convalesc
patient
fig
minimum
detect
dose
pgml
signific
differ
percentag
lymphocyt
acutephas
sar
patient
compar
healthi
control
p
oneway
anova
differ
report
howev
percentag
lymphocyt
decreas
significantli
p
oneway
anova
parallel
result
report
elsewher
observ
decreas
cell
percentag
sar
patient
statist
correl
steroid
use
correl
coeffici
p
spearman
correl
analysi
chang
lymphocyt
percentag
correl
coeffici
p
spearman
correl
analysi
signific
chang
ratio
acutephas
patient
compar
healthi
control
p
oneway
anova
fig
also
signific
chang
amount
total
lymphocyt
lymphocyt
pbmc
isol
convalesc
patient
compar
healthi
control
p
fig
tabl
similarli
express
b
lymphocyt
substanti
alter
convalesc
patient
compar
healthi
control
lymphocyt
increas
convalesc
patient
p
lymphocyt
compar
normal
control
latter
statist
signific
p
memori
lymphocyt
decreas
p
memori
lymphocyt
convalesc
patient
compar
healthi
control
latter
signific
p
tabl
observ
alter
cell
memori
cell
percentag
correl
use
corticosteroid
correl
coeffici
p
respect
spearman
correl
analysi
five
test
gener
humor
immun
paramet
iga
igg
igm
notabl
increas
within
one
month
diseas
onset
peak
week
decreas
gradual
normal
level
within
month
increas
statist
signific
p
fig
b
seroposit
rate
specif
igm
igg
antibodi
respond
sarscov
increas
sar
patient
day
rate
increas
continu
increas
highest
level
day
fig
day
specif
igmposit
rate
drop
wherea
iggposit
rate
remain
stabl
around
similarli
dynam
posit
rate
titer
specif
igm
igg
elev
along
diseas
develop
demonstr
elev
optic
densiti
day
peak
day
respect
control
od
valu
healthi
control
day
titer
two
specif
antibodi
decreas
eventu
drop
approxim
half
peak
valu
fig
studi
found
infect
sarscov
trigger
vigor
immun
disturb
character
follow
typic
antivir
nonspecif
specif
humor
respons
perturb
cytokin
chemokin
level
sever
impair
cellular
immun
includ
lymphopenia
acut
phase
loss
memori
cell
convalesc
phase
acutephas
sar
patient
serum
level
ifnc
chang
significantli
level
tnfb
decreas
tgfb
level
increas
significantli
shown
fig
suggest
complex
predominantli
pattern
trigger
sarscov
infect
acutephas
differ
result
previou
report
found
pattern
respons
reason
differ
unknown
interestingli
pattern
statist
correl
administr
steroid
although
steroid
inhibit
cytokin
product
also
could
due
use
ribavirin
ribavirin
switch
cytokin
respons
pattern
one
evid
observ
studi
thu
differ
may
due
variat
studi
popul
genet
heterogen
sarscov
strain
discrep
appli
analyt
method
previou
work
shown
cytoplasm
parasit
directli
activ
nuclear
factorkappa
b
nfjb
pathway
anoth
recent
report
show
fig
percentag
total
number
pbmc
percentag
lymphocyt
total
number
cell
ratio
acutephas
sar
patient
percentag
lymphocyt
chang
significantli
acutephas
p
oneway
anova
wherea
percentag
lymphocyt
decreas
significantli
vs
control
convalesc
group
p
oneway
anova
alter
cell
percentag
correl
statist
steroid
use
correl
coeffici
p
spearman
correl
analysi
wherea
lymphocyt
correl
coeffici
p
spearman
correl
analysi
percentag
lymphocyt
acut
patient
b
percentag
lymphocyt
acutephas
patient
c
percentag
lymphocyt
acutephas
patient
p
oneway
anova
data
collect
condit
indic
section
flow
cytometri
analisi
sar
protein
contain
superantigen
domain
residu
mimic
tcell
receptor
abv
chain
protein
moreov
entri
sarscov
lymphocyt
well
establish
therefor
postul
cytoplasm
sarscov
could
possibl
activ
cytokin
releas
wellknown
immun
respons
inhibit
cellular
immun
facilit
induct
humor
immun
help
clear
persist
viral
infect
immun
respons
may
benefit
elimin
persist
extracellular
coronaviru
particl
combin
ribavirin
corticosteroid
empir
therapi
sar
administr
steroid
sar
fig
spectrum
nonspecif
specif
humor
immun
patient
sar
gener
humor
immun
paramet
iga
igg
igm
evalu
automat
serum
sampl
use
beckman
array
system
specificantibodi
elisa
assay
polystyren
micropl
precoat
lysat
sarscov
sarscov
infect
cell
sera
dilut
conjug
murin
antihuman
igg
use
second
antibodi
level
iga
igg
igm
j
light
chain
notabl
elev
first
month
sar
infect
decreas
normal
level
within
month
thereaft
seroposit
rate
titer
specif
igm
igg
antibodi
respond
sarscov
increas
peak
week
onset
sar
iga
igg
igm
b
c
posit
rate
specif
igg
igm
respond
sarscov
patient
sar
optic
densiti
specif
igg
igm
respond
sarscov
patient
sar
w
week
ctr
control
month
od
optic
densiti
note
lymphocyt
increas
lymphocyt
decreas
patient
sar
compar
normal
control
p
oneway
anova
howev
consider
chang
cell
number
pbmc
convalesc
patient
sar
flow
cytometri
p
oneway
anova
rate
chang
column
stand
alter
percentag
patient
compar
normal
control
believ
base
follow
virus
includ
coronavirus
induc
ifnc
product
elicit
immun
respons
mainli
pathway
massiv
releas
ifnc
tnfa
contribut
pathogenesi
sar
steroid
abl
antagon
action
proinflammatori
cytokin
howev
steroid
therapi
ineffect
acut
respiratori
distress
syndrom
doubt
sar
consider
side
effect
includ
avascular
necrosi
bone
opportunist
infect
hepat
damag
metabol
disturb
unlik
coronaviru
sar
present
domin
instead
exacerb
immun
respons
studi
might
one
reason
explain
ineffect
steroid
therapi
sar
domin
also
suggest
steroid
therapi
may
unnecessari
modul
acutephas
advers
affect
clearanc
intracellular
sarscov
futur
studi
direct
improv
immun
function
patient
restor
balanc
develop
effect
antivir
therapi
control
replic
sarscov
need
chemokin
play
essenti
role
develop
inflamm
respons
viral
infect
acut
respiratori
virus
commonli
induc
inflammatori
chemokin
amplifi
inflammatori
respons
lead
immunopatholog
sinc
bchemokin
rant
predominantli
attract
monocyt
elev
observ
acutephas
patient
like
reflect
potenti
role
monocyt
pathogenesi
sar
cell
well
monocyt
macrophag
produc
rant
acutephas
patient
experienc
sever
decreas
cell
impair
two
subtyp
cell
may
account
observ
downregul
rant
acutephas
reason
signific
downregul
rant
convalesc
patient
unclear
cell
decreas
phase
differenti
cell
virusspecif
cell
critic
induct
effect
antivir
immun
respons
howev
sar
patient
studi
show
remark
decreas
cell
acutephas
compar
found
previou
report
suppos
phenomenon
relat
either
viral
infect
lymphocyt
apoptosi
lymphocyt
humor
mediat
cytokin
downregul
lymphocyt
differenti
use
cortisol
studi
decreas
cell
definit
relat
administr
steroid
reason
chang
two
subset
cell
could
fulli
explain
use
cortisol
addit
also
found
signific
elev
tgfb
patient
acutephas
two
cytokin
potent
downregul
cellmedi
immun
respons
tgfbwa
shown
involv
pulmonari
fibrosi
common
sar
thu
overexpress
two
cytokin
studi
strongli
suggest
involv
mediat
lymphocyt
damag
sar
interpret
conjunct
impair
cell
predomin
chang
rant
indic
patient
suffer
sever
immun
damag
especi
cell
immun
imbalanc
chemokin
cytokin
level
may
involv
pathogenesi
sar
acutephas
viral
infect
usual
stimul
lymphocyt
lead
rapid
increas
lymphocyt
sar
lymphocyt
circul
decreas
acutephas
demonstr
immunoelectron
microscopi
rais
concern
effect
sarscov
infect
immun
memori
patient
observ
immun
memori
function
convalesc
patient
measur
peripher
memori
cell
surpris
sar
patient
also
experienc
select
damag
peripher
memori
lymphocyt
phenomenon
statist
correl
induct
glucocorticoid
therapi
even
though
steroid
induc
inhibit
memori
cell
develop
moreov
lymphopenia
ascrib
exogen
steroid
taken
togeth
may
suggest
dramat
reduct
memori
cell
caus
mechan
consider
data
shown
mainten
memori
cell
fundament
regul
cytokin
domin
associ
increas
apoptosi
memori
cell
thu
hypothes
select
damag
cellular
immun
especi
unusu
loss
memori
lymphocyt
much
like
result
prolong
overexpress
tgfb
protect
memori
cell
crucial
antivir
immun
studi
impli
case
anoth
sarscov
attack
immun
system
patient
may
unabl
effect
respond
pathogen
therefor
patient
could
reinfect
sarscov
reason
immun
enhanc
measur
may
benefici
patient
also
studi
defin
differenti
function
sarscovinfect
lymphocyt
need
clarifi
whether
chang
cell
subset
followup
indic
enhanc
sarscov
progress
initi
infect
recent
research
demonstr
signal
trigger
infectionvaccin
determin
extent
natur
memori
cell
develop
take
consider
possibl
entri
sarscov
lymphocyt
abl
stimul
cytokin
imbal
consequ
caus
damag
cellular
immun
presum
apoptot
manner
admittedli
sarsspecif
cell
would
repres
paramet
precis
cell
immun
sarscov
necessari
follow
sar
patient
longer
time
investig
immun
function
character
specif
cell
patient
fortun
sarscov
infect
induc
deplet
b
lymphocyt
abl
effici
trigger
substanti
nonspecif
specif
humor
immun
cohort
studi
indic
preserv
b
cell
function
recent
neutral
antibodi
sarscov
gener
immun
mice
either
subunit
dna
vaccin
sarscov
shown
induc
protect
immun
anim
suggest
possibl
rational
develop
sarscov
vaccin
abl
induc
neutral
antibodi
sarscov
novel
coronaviru
biolog
fulli
understood
date
find
suggest
sarscov
infect
elicit
gener
specif
humor
immun
may
deplet
cellular
immun
overexpress
tgfb
may
respons
immunopathi
sar
studi
provid
basi
better
understand
biolog
featur
sarscov
valuabl
patient
manag
design
effect
vaccin
sarscov
